EMA’s safety committee recommends suspending preterm birth drugs

The Eu­ro­pean Med­i­cines Agency is tak­ing aim at preterm birth drugs, with the agency’s safe­ty com­mit­tee rec­om­mend­ing that med­i­cines con­tain­ing 17-hy­drox­yprog­es­terone caproate, al­so known as 17-OH­PC, be sus­pend­ed.

A re­view by the safe­ty com­mit­tee “con­clud­ed that there is a pos­si­ble but un­con­firmed risk of can­cer in peo­ple ex­posed to 17-OH­PC in the womb,” as well as ques­tions around its ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.